Medtronic touts insertable monitor, algorhythm data
Medtronic (NYSE:MDT) touted data presented at HRS 2017 it said show the benefits of its inserable cardiac monitors and cardiac rhythm management algorhythm.
Eighteen-month data from the 385-patient Reveal AF study showed that continuous monitoring with Medtronic’s Reveal XT or Reveal Linq ICMs delivered an AF detection rate of 29.3% in previously undiagnosed high-risk patients; between 18 and 30 months the detection rate was 40%. Because the detection rate was only 6.2% at 30 days, Reveal AF indicates that more than 75% of high-risk patients would have gone undetected.
There was at least 1 clinical action for nearly76% of patients with detected AF at 18 months, with more than half of those prescribed for oral antigoagulates, Medtronic said.
“Detection of AF utilizing minimally invasive insertable cardiac monitors in a high-risk population combined with appropriate AF treatment could prevent many initial strokes,” principal investigator Dr. James Reiffel, professor emeritus of medicine at New York CIty’s Columbia Presbyterian Medical Center, said in prepared remarks. “Findings from the Reveal AF study show that the rate of AF in patients at high risk for AF and thus stroke, but with no prior history of AF, is significant, raising important public health implications on early screening and prevention of stroke in this demographic group.”
“AF is often undetected with conventional methods and only first diagnosed after the occurrence of a serious complication such as stroke which can result in significant impact to quality of life and even death,” added cardiac rhythm & heart failure medical director Dr. Robert Kowal. “The Reveal AF study provides important information to influence how physicians monitor high-risk patients to screen and treat AF, potentially preventing stroke from occurring.”
Data on the AdaptivCRT algorithm used with some of Medtronic’s cardiac resynchronization therapy devices showed that they help determine the effectiveness of therapy and lowered the rate of AF in heart failure patients. A 40,000-patient observational study comparing CRT-Ds with AdaptivCRT and conventional bi-ventricular pacing showed that the AdaptivCRT arm showed a 35%
“These outcomes further confirm the benefits of these advanced cardiac resynchronization therapy technologies delivered in a contemporary real-world clinical setting,” Dr. Jonathan Hsu, of the University of California, San Diego, said in prepared remarks. “AdaptivCRT gives us more insights and automatically makes adjustments based on each patient’s unique needs, and our study suggests that its use is associated with a decreased risk of developing atrial fibrillation.”
“Medtronic is committed to providing the most advanced technologies that are shown to help improve the delivery and effectiveness of cardiac resynchronization therapy in both controlled and real-world environments,” added heart failure general manager Dr. David Steinhaus. “Our portfolio of cardiac devices and technologies continues to lead the way in personalized care, creating better solutions and improving individual patient outcomes.”
NEXT: J&J’s Biosense Webster debuts 1st-in-human results for RF balloon cath